Wall Street Zen Upgrades Unicycive Therapeutics (NASDAQ:UNCY) to "Hold"

Key Points

• Unicycive Therapeutics has been upgraded by Wall Street Zen from a "sell" to a "hold" rating in a recent research note.
• Benchmark raised its price target for Unicycive shares to $21.00, while the average consensus price target is $57.00.
• Institutional ownership of Unicycive Therapeutics is around 40.42%, with notable increases in holdings by Vivo Capital LLC and JPMorgan Chase & Co.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Several other research firms have also weighed in on UNCY. Benchmark lifted their price objective on shares of Unicycive Therapeutics to $21.00 and gave the stock a "speculative buy" rating in a research note on Monday, September 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Unicycive Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $57.00.

Unicycive Therapeutics Stock Performance

Shares of UNCY stock opened at $4.44 on Friday. Unicycive Therapeutics has a 52-week low of $3.53 and a 52-week high of $11.00. The stock has a market cap of $78.41 million, a PE ratio of -1.08 and a beta of 1.86. The firm's 50 day moving average price is $4.24 and its two-hundred day moving average price is $5.24.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.18. As a group, sell-side analysts predict that Unicycive Therapeutics will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of Unicycive Therapeutics

Several hedge funds have recently bought and sold shares of UNCY. Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock valued at $6,537,000 after purchasing an additional 1,400,000 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after buying an additional 21,525 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in Unicycive Therapeutics during the second quarter worth $55,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.